Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Patients with Heart Failure
41%
Heart Failure
39%
Heart Failure with Preserved Ejection Fraction (HFpEF)
29%
Chronic Heart Failure
27%
Biology Study
21%
Tailored Treatment
21%
Worsening Heart Failure
16%
All-cause Mortality
14%
95% Confidence Interval
13%
Heart Failure Patients
12%
Chronic Kidney Disease
11%
Heart Failure Hospitalization
11%
Medical Therapy
11%
Pathophysiological Pathways
11%
Mitral Regurgitation
10%
Preserved Ejection Fraction
10%
Hazard Ratio
9%
Left Ventricular Ejection Fraction
9%
N-terminal pro-B-type Natriuretic Peptide (NT-proBNP)
9%
Reduced Ejection Fraction
9%
Heart Failure Therapy
8%
Angiotensin-converting Enzyme Inhibitor (ACEi)
8%
Quality of Life
7%
Atrial Fibrillation
7%
Heart Failure Severity
6%
Up-titration
6%
New-onset Heart Failure
6%
Therapy Optimization
6%
Response to Treatment
6%
Congestion
6%
Spot Urine
6%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
6%
Kansas City Cardiomyopathy Questionnaire
6%
Clinical Characteristics
5%
Europe
5%
Risk Score
5%
Disease Severity
5%
Carbohydrates
5%
EuroQol-5 Dimensions
5%
Proteomic Approach
5%
Targetable
5%
Beneficial Properties
5%
Muscle Wasting
5%
Cardiorenal Syndrome
5%
Disease Pathogenesis
5%
Urinary Markers
5%
Non-adherence
5%
Urinary Creatinine
5%
Severe Mitral Regurgitation
5%
High-density Lipoprotein Cholesterol (HDL-C)
5%
Cathepsin D
5%
Telomere Length
5%
Validation Studies
5%
Failure Treatment
5%
Failure Characteristics
5%
Interleukin-17 (IL-17)
5%
Disease Potential
5%
Adverse Remodeling
5%
Protein Intake
5%
European Centers
5%
Translational Approach
5%
Surrogate Endpoint
5%
Leukocyte Telomere Length
5%
Change Impact
5%
Novel Therapeutic Targets
5%
Clinical Response
5%
Gut Barrier Dysfunction
5%
Plasma Proteomics
5%
Disease Progression
5%
Clinical Role
5%
Biomarker Changes
5%
Surrogate Marker
5%
Proteomic Profile
5%
Iron Deficiency
5%
Left Atrial Function
5%
Inflammatory Process
5%
Heart Atrial
5%
Geographical Differences
5%
Heart Failure Outcomes
5%
Heart Failure Association
5%
Clinical Pathophysiology
5%
Prospective multicenter Study
5%
Early Phase Clinical Trials
5%
Concentric Remodeling
5%
Clinical Outcome Assessment
5%
High-density Lipoprotein Function
5%
Clinical Impact
5%
Clinical Profile
5%
Clinical Outcomes
5%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
All Cause Mortality
13%
Heart Failure with Reduced Ejection Fraction
10%
Biological Marker
10%
Chronic Kidney Failure
10%
Pathophysiology
7%
Myocardial Disease
6%
Cardiovascular Mortality
6%
Syndrome
6%
High Density Lipoprotein Cholesterol
5%
Heart Failure with Preserved Ejection Fraction
5%
Mitral Valve Regurgitation
5%
Disease Severity
5%
Carbohydrates
5%
Cathepsin D
5%
Growth Differentiation Factor 15
5%
High Density Lipoprotein
5%
Muscarinic Receptor
5%
Anemia
5%
Selenium
5%
Autoantibodies
5%
Iron Deficiency
5%
Dipeptidyl Carboxypeptidase Inhibitor
5%
Medicine and Dentistry
Congestive Heart Failure
54%
Heart Failure with Reduced Ejection Fraction
10%
Carbohydrates
10%
Hazard Ratio
10%
Ejection Fraction
7%
Biological Marker
7%
Acute Decompensated Heart Failure
6%
Pathophysiology
6%
Urine Sampling
6%
Urinary System
6%
Myocardial Disease
6%
Carbohydrate Antigen
6%
Quality of Life
6%
Mitral Insufficiency
5%
Protein Intake
5%
Outcome Assessment
5%
Anemia
5%
Gut
5%
Liquid Chromatography-Mass Spectrometry
5%
Kidney Tubule Function
5%
Iron Deficiency
5%
Disease Marker
5%